Highlights
- Chimeric Therapeutics has completed enrolment for ADVENT-AML Phase 1B clinical trial for the dose-finding stage.
- In the next phase, the company will enrol newly diagnosed AML (Acute Myeloid Leukemia) patients who are elderly or ineligible for transplantation.
- ADVENT-AML is the first study to assess the effectiveness of combination of CORE NKs and standard of care for many AML patients.
Chimeric Therapeutics (ASX:CHM) has successfully completed enrolment for its ADVENT-AML Phase 1B clinical trial in AML for the dose-finding phase, with no dose-limiting toxicities or unexpected safety findings. In the next phase of the study, the company will recruit those patients who are newly diagnosed with AML, elderly or unsuitable for intensive chemotherapy or allogeneic stem cell transplant.
Details of the ADVENT-AML (NCT05834244) Phase 1B clinical trial
Data source: Company update
Data source: Company update
Following the update, CHM share price has surged by 5.55% to trade at AU$0.009 apiece at the time of drafting on 24 October 2024.